Hand-foot syndrome due to sorafenib in hepatocellular carcinoma treated with vitamin E without dose modification; A preliminary clinical study

Duman B. B., Kara B., KARA İ. O., Demiryurek H., Aksungur E.

JOURNAL OF BUON, cilt.16, sa.4, ss.759-764, 2011 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16 Sayı: 4
  • Basım Tarihi: 2011
  • Dergi Adı: JOURNAL OF BUON
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.759-764
  • Çukurova Üniversitesi Adresli: Evet

Özet

Purpose: Sorafenib has been found to have significant clinical activity against hepatocellular carcinoma (HCC). Hand-foot skin syndrome (HFS) has been described with the usage of sorafenib. It is a dose-limiting toxicity and may lead to compromised efficacy because of dose reduction.